Flightpath Biosciences, Inc. is a biotechnology startup focused on developing innovative treatments and diagnostics for infectious diseases. The company operates in the biotech and healthcare market, specifically targeting bacterial pathogens that cause significant health issues, such as Lyme disease and syphilis. Flightpath's primary clients include healthcare providers, research institutions, and pharmaceutical companies.

Flightpath's business model revolves around the development and commercialization of microbiome-sparing therapeutics and diagnostics. This means they create treatments that target harmful bacteria without disrupting the beneficial bacteria in the human body. One of their key products is FP-100, a developmental antibiotic licensed from Northeastern University, which selectively targets spirochetal pathogens like Borrelia burgdorferi, the bacteria responsible for Lyme disease. Additionally, they are working on FP-101, an FDA-approved IV antibiotic repurposed for oral delivery to treat persistent Lyme infections.

The company generates revenue through the licensing of their proprietary antibiotics and diagnostics, as well as through partnerships and collaborations with other biotech firms and research institutions. By advancing their research and development (R&D) programs, Flightpath aims to bring new, effective treatments to market, addressing unmet medical needs and improving patient outcomes.

Flightpath's team includes experts in microbiology, immunology, and biotechnology, who work closely with the CEO on strategic business development and innovation initiatives. Their collaborative approach with data science and bioinformatics partners helps them understand the genetic and transcriptomic impacts of their drugs, leading to new discoveries and potential new diagnostics and therapeutics.

Keywords: biotechnology, infectious diseases, microbiome-sparing, antibiotics, diagnostics, Lyme disease, syphilis, R&D, healthcare, therapeutics.